Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin. 2024;8(4):s408. doi:10.25251/skin.8.supp.408